Liposomal Doxorubicin Market 2027 by Product Type, Application | The Insight Partners

Liposomal Doxorubicin Market Forecast to 2027 - Covid-19 Impact and Global Analysis - by Product Type (JandJ (Doxil/Caelyx), Sun Pharma (Lipodox), Teva (Myocet), Others); Application (Bone Sarcoma, Breast Cancer, Endometrial Cancer, Gastric Cancer, Kaposi Sarcoma, Kidney Cancer, Leukemia, Liver Cancer, Multiple Myeloma, Other Applications, Ovarian Cancer)

Report Code: TIPRE00008182 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Doxorubicin is a chemotherapy medication used to treat cancer. Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated liposomes. These spheres keep the doxorubicin in the bloodstream longer, so that more of the drug reaches the cancer cells. Doxorubicin includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia and is given by injection into a vein.

MARKET DYNAMICS

The liposomal doxorubicin market is anticipated to owing to the growing availability of the product. However, some side-effects associated with Liposomal Doxorubicin is expected to hinder the growth of the market over the forecast period. Moreover, the increasing involvement of significant private players to reduce redundancies and complexities in the global supply chain is expected to benefit the growth of the market in the forecast period.

MARKET SCOPE

The "Liposomal Doxorubicin Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of in liposomal doxorubicin market with detailed market segmentation by product type, application and geography. The liposomal doxorubicin market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading in liposomal doxorubicin market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The liposomal doxorubicin market is segmented on the basis of product type and application. Based on product type the market is segmented as J&J (doxil/caelyx), sun pharma (lipodox), teva (myocet) and others. On the basis of application the market is categorized bone sarcoma, breast cancer, endometrial cancer, gastric cancer, kaposi sarcoma, kidney cancer, leukemia, liver cancer, multiple myeloma, other applications and ovarian cancer.



Get more information on this report :

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the in liposomal doxorubicin market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The liposomal doxorubicin market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting liposomal doxorubicin market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the liposomal doxorubicin market in these regions.




Get more information on this report :

MARKET PLAYERS


The report covers key developments in the in liposomal doxorubicin market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from in liposomal doxorubicin market are anticipated to have lucrative growth opportunities in the future with the rising demand for in liposomal doxorubicin market in the global market. Below mentioned is the list of few companies engaged in the liposomal doxorubicin market.

The report also includes the profiles of key in liposomal doxorubicin market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Cadila Pharmaceuticals
  •  Cipla, Inc.
  •  GlaxoSmithKline plc.
  •  Johnson & Johnson Services, Inc.
  •  Merck & Co.
  •  Pfizer Inc.
  •  Sanofi
  •  Sigma-Aldrich Co.
  •  SRS Pharmaceuticals Pvt. Ltd.
  •  Sun Pharmaceutical Industries Ltd.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Liposomal Doxorubicin Market - By Product Type
1.3.2 Liposomal Doxorubicin Market - By Application
1.3.3 Liposomal Doxorubicin Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS


3. RESEARCH METHODOLOGY


4. LIPOSOMAL DOXORUBICIN MARKET LANDSCAPE

4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. LIPOSOMAL DOXORUBICIN MARKET - KEY MARKET DYNAMICS

5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

6. LIPOSOMAL DOXORUBICIN MARKET - GLOBAL MARKET ANALYSIS

6.1. LIPOSOMAL DOXORUBICIN - GLOBAL MARKET OVERVIEW
6.2. LIPOSOMAL DOXORUBICIN - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. LIPOSOMAL DOXORUBICIN MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT TYPE

7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. JANDJ (DOXIL/CAELYX)
7.3.1. Overview
7.3.2. JandJ (Doxil/Caelyx) Market Forecast and Analysis
7.4. SUN PHARMA (LIPODOX)
7.4.1. Overview
7.4.2. Sun Pharma (Lipodox) Market Forecast and Analysis
7.5. TEVA (MYOCET)
7.5.1. Overview
7.5.2. Teva (Myocet) Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis

8. LIPOSOMAL DOXORUBICIN MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION

8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. BONE SARCOMA
8.3.1. Overview
8.3.2. Bone Sarcoma Market Forecast and Analysis
8.4. BREAST CANCER
8.4.1. Overview
8.4.2. Breast Cancer Market Forecast and Analysis
8.5. ENDOMETRIAL CANCER
8.5.1. Overview
8.5.2. Endometrial Cancer Market Forecast and Analysis
8.6. GASTRIC CANCER
8.6.1. Overview
8.6.2. Gastric Cancer Market Forecast and Analysis
8.7. KAPOSI SARCOMA
8.7.1. Overview
8.7.2. Kaposi Sarcoma Market Forecast and Analysis
8.8. KIDNEY CANCER
8.8.1. Overview
8.8.2. Kidney Cancer Market Forecast and Analysis
8.9. LEUKEMIA
8.9.1. Overview
8.9.2. Leukemia Market Forecast and Analysis
8.10. LIVER CANCER
8.10.1. Overview
8.10.2. Liver Cancer Market Forecast and Analysis
8.11. MULTIPLE MYELOMA
8.11.1. Overview
8.11.2. Multiple Myeloma Market Forecast and Analysis
8.12. OTHER APPLICATIONS
8.12.1. Overview
8.12.2. Other Applications Market Forecast and Analysis
8.13. OVARIAN CANCER
8.13.1. Overview
8.13.2. Ovarian Cancer Market Forecast and Analysis

9. LIPOSOMAL DOXORUBICIN MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS

9.1. NORTH AMERICA
9.1.1 North America Liposomal Doxorubicin Market Overview
9.1.2 North America Liposomal Doxorubicin Market Forecasts and Analysis
9.1.3 North America Liposomal Doxorubicin Market Forecasts and Analysis - By Product Type
9.1.4 North America Liposomal Doxorubicin Market Forecasts and Analysis - By Application
9.1.5 North America Liposomal Doxorubicin Market Forecasts and Analysis - By Countries
9.1.5.1 United States Liposomal Doxorubicin Market
9.1.5.1.1 United States Liposomal Doxorubicin Market by Product Type
9.1.5.1.2 United States Liposomal Doxorubicin Market by Application
9.1.5.2 Canada Liposomal Doxorubicin Market
9.1.5.2.1 Canada Liposomal Doxorubicin Market by Product Type
9.1.5.2.2 Canada Liposomal Doxorubicin Market by Application
9.1.5.3 Mexico Liposomal Doxorubicin Market
9.1.5.3.1 Mexico Liposomal Doxorubicin Market by Product Type
9.1.5.3.2 Mexico Liposomal Doxorubicin Market by Application
9.2. EUROPE
9.2.1 Europe Liposomal Doxorubicin Market Overview
9.2.2 Europe Liposomal Doxorubicin Market Forecasts and Analysis
9.2.3 Europe Liposomal Doxorubicin Market Forecasts and Analysis - By Product Type
9.2.4 Europe Liposomal Doxorubicin Market Forecasts and Analysis - By Application
9.2.5 Europe Liposomal Doxorubicin Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Liposomal Doxorubicin Market
9.2.5.1.1 Germany Liposomal Doxorubicin Market by Product Type
9.2.5.1.2 Germany Liposomal Doxorubicin Market by Application
9.2.5.2 France Liposomal Doxorubicin Market
9.2.5.2.1 France Liposomal Doxorubicin Market by Product Type
9.2.5.2.2 France Liposomal Doxorubicin Market by Application
9.2.5.3 Italy Liposomal Doxorubicin Market
9.2.5.3.1 Italy Liposomal Doxorubicin Market by Product Type
9.2.5.3.2 Italy Liposomal Doxorubicin Market by Application
9.2.5.4 Spain Liposomal Doxorubicin Market
9.2.5.4.1 Spain Liposomal Doxorubicin Market by Product Type
9.2.5.4.2 Spain Liposomal Doxorubicin Market by Application
9.2.5.5 United Kingdom Liposomal Doxorubicin Market
9.2.5.5.1 United Kingdom Liposomal Doxorubicin Market by Product Type
9.2.5.5.2 United Kingdom Liposomal Doxorubicin Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Liposomal Doxorubicin Market Overview
9.3.2 Asia-Pacific Liposomal Doxorubicin Market Forecasts and Analysis
9.3.3 Asia-Pacific Liposomal Doxorubicin Market Forecasts and Analysis - By Product Type
9.3.4 Asia-Pacific Liposomal Doxorubicin Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Liposomal Doxorubicin Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Liposomal Doxorubicin Market
9.3.5.1.1 Australia Liposomal Doxorubicin Market by Product Type
9.3.5.1.2 Australia Liposomal Doxorubicin Market by Application
9.3.5.2 China Liposomal Doxorubicin Market
9.3.5.2.1 China Liposomal Doxorubicin Market by Product Type
9.3.5.2.2 China Liposomal Doxorubicin Market by Application
9.3.5.3 India Liposomal Doxorubicin Market
9.3.5.3.1 India Liposomal Doxorubicin Market by Product Type
9.3.5.3.2 India Liposomal Doxorubicin Market by Application
9.3.5.4 Japan Liposomal Doxorubicin Market
9.3.5.4.1 Japan Liposomal Doxorubicin Market by Product Type
9.3.5.4.2 Japan Liposomal Doxorubicin Market by Application
9.3.5.5 South Korea Liposomal Doxorubicin Market
9.3.5.5.1 South Korea Liposomal Doxorubicin Market by Product Type
9.3.5.5.2 South Korea Liposomal Doxorubicin Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Liposomal Doxorubicin Market Overview
9.4.2 Middle East and Africa Liposomal Doxorubicin Market Forecasts and Analysis
9.4.3 Middle East and Africa Liposomal Doxorubicin Market Forecasts and Analysis - By Product Type
9.4.4 Middle East and Africa Liposomal Doxorubicin Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Liposomal Doxorubicin Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Liposomal Doxorubicin Market
9.4.5.1.1 South Africa Liposomal Doxorubicin Market by Product Type
9.4.5.1.2 South Africa Liposomal Doxorubicin Market by Application
9.4.5.2 Saudi Arabia Liposomal Doxorubicin Market
9.4.5.2.1 Saudi Arabia Liposomal Doxorubicin Market by Product Type
9.4.5.2.2 Saudi Arabia Liposomal Doxorubicin Market by Application
9.4.5.3 U.A.E Liposomal Doxorubicin Market
9.4.5.3.1 U.A.E Liposomal Doxorubicin Market by Product Type
9.4.5.3.2 U.A.E Liposomal Doxorubicin Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Liposomal Doxorubicin Market Overview
9.5.2 South and Central America Liposomal Doxorubicin Market Forecasts and Analysis
9.5.3 South and Central America Liposomal Doxorubicin Market Forecasts and Analysis - By Product Type
9.5.4 South and Central America Liposomal Doxorubicin Market Forecasts and Analysis - By Application
9.5.5 South and Central America Liposomal Doxorubicin Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Liposomal Doxorubicin Market
9.5.5.1.1 Brazil Liposomal Doxorubicin Market by Product Type
9.5.5.1.2 Brazil Liposomal Doxorubicin Market by Application
9.5.5.2 Argentina Liposomal Doxorubicin Market
9.5.5.2.1 Argentina Liposomal Doxorubicin Market by Product Type
9.5.5.2.2 Argentina Liposomal Doxorubicin Market by Application

10. INDUSTRY LANDSCAPE

10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

11. LIPOSOMAL DOXORUBICIN MARKET, KEY COMPANY PROFILES

11.1. CADILA PHARMACEUTICALS
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. CIPLA, INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. GLAXOSMITHKLINE PLC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. JOHNSON AND JOHNSON SERVICES, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MERCK AND CO.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. PFIZER INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. SANOFI
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. SIGMA-ALDRICH CO.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SRS PHARMACEUTICALS PVT. LTD.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SUN PHARMACEUTICAL INDUSTRIES LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments

12. APPENDIX

12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Cadila Pharmaceuticals
2. Cipla, Inc.
3. GlaxoSmithKline plc.
4. Johnson & Johnson Services, Inc.
5. Merck & Co.
6. Pfizer Inc.
7. Sanofi
8. Sigma-Aldrich Co.
9. SRS Pharmaceuticals Pvt. Ltd.
10. Sun Pharmaceutical Industries Ltd.
TIPRE00008182
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking